Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in a deal worth over $1 ...